secwatch.observer — SEC 8-K summary
======================================

Issuer:     Vivos Therapeutics, Inc. (VVOS)
CIK:        0001716166
Form:       8-K
Filed at:   2024-08-15T23:59:59+00:00
Accession:  0001493152-24-032453
Event type: earnings
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Vivos Therapeutics Q2 revenue up 19% YoY to $4.1M; operating expenses down 31%
------------------------------------------------------------------------------

- Revenue $4.1M vs $3.4M YoY; gross margin improved to 65% from 62%.
- Operating loss reduced 57% YoY; eight straight quarters of YoY expense cuts.
- Cash $6.9M; stockholders' equity $6.3M; expects positive cash flow in early 2025.
- Received Medicare reimbursement for CARE oral devices; closed $7.5M equity investment from New Seneca Partners.
- New strategic alliance with sleep testing centers in Colorado; pilot showed 79% of patients chose Vivos therapy over CPAP.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1716166/000149315224032453/0001493152-24-032453-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1716166/000149315224032453/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-24-032453

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer